t
AOTI Inc. was informed on 6 May 2025 that Mr Douglas Lefort, Non-executive Chairman, bought 31,094 common shares at 80 pence per share on the London Stock Exchange. Following this purchase, Mr Lefort's beneficial holding, including that of his spouse, increased to 1,482,715 Common Shares, representing approximately 1.39% of the Company's issued share capital.
| Date | 7 May 2025 |
| Time | 07:00:11 |
| Category | Director/PDMR dealings |
| ID | 6503H |
7 May 2025
AOTI Inc.
(the "Company")
Director/PDMR Shareholding - Share purchase
The Company was informed on 6 May 2025 that Mr Douglas Lefort, Non-executive Chaiman of the Company, bought a total of 31,094 common shares of $0.00001 in the capital of the Company ("Common Shares") at 80 pence per share.
Following the purchase, Mr Lefort's beneficial holding (including that of his spouse) and the total interest in the Company has increased to 1,482,715 Common Shares, representing approximately 1.39% of the Company's issued share capital.
The below notification, made in accordance with Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
|||||
|
a)
|
Name
|
Mr Douglas Lefort |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Non-executive Chairman
|
||||
|
b)
|
Initial notification /Amendment
|
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
|||||
|
a)
|
Name
|
AOTI Inc. |
||||
|
b)
|
LEI
|
213800ZGCNDSTWIRK687 |
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Common shares of $0.00001 each
ISIN: US03690C1027 |
||||
|
b)
|
Nature of the transaction
|
Purchase of Common Shares by Mr Lefort on 6 May 2025
|
||||
|
c)
|
Price(s) and volume(s) |
|
||||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
NA
NA |
||||
|
e)
|
Date of the transaction
|
6 May 2025 |
||||
|
f)
|
Place of the transaction
|
London Stock Exchange |
||||
For further information please contact:
|
AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer
|
+44 (0)20 3727 1000 |
|
Peel Hunt LLP (Nominated Adviser and Broker) Dr. Christopher Golden, James Steel
|
+44 (0)20 7418 8900 |
|
FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins, Alex Davis |
+44 (0)20 3727 1000 |
ABOUT AOTI, INC.
AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO2®) therapy has demonstrated in differentiating, robust, double-blinded randomised controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalisations and 71 per cent reduction in amputations over 12 months. TWO2® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO2® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net